Adam P Conner

US Patent:

20180355021, Dec 13, 2018

Filed:

Jun 8, 2018

Appl. No.:

16/003926

Inventors:

- Vero Beach FL, US
H. Bryan Brewer - Potomac MD, US
Hassibullah Akeefe - San Ramon CA, US
Adam Paul Conner - Warsaw IN, US
Timothy Jon Perlman - Pleasanton CA, US

International Classification:

C07K 14/775
A61K 9/127
B01D 15/42
B01D 15/00
B01D 11/04
A61K 38/17
A61K 31/685
G01N 33/92

Abstract:

The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.

US Patent:

20170174747, Jun 22, 2017

Filed:

Mar 9, 2017

Appl. No.:

15/454263

Inventors:

- Vero Beach FL, US
H. BRYAN BREWER - Potomac MD, US
HASSIBULLAH AKEEFE - San Ramon CA, US
ADAM PAUL CONNER - Warsaw IN, US
TIMOTHY JON PERLMAN - Pleasanton CA, US

International Classification:

C07K 14/775
B01D 15/42
B01D 11/04
A61K 38/17

Abstract:

The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.

US Patent:

20160324925, Nov 10, 2016

Filed:

Jul 20, 2016

Appl. No.:

15/214683

Inventors:

- Vero Beach FL, US
H. Bryan Brewer - Potomac MD, US
Hassibullah Akeefe - San Ramon CA, US
Adam Paul Conner - Warsaw IN, US
Timothy Jon Perlman - Pleasanton CA, US

International Classification:

A61K 38/17
B01D 15/00
B01D 11/04
C07K 14/775
B01D 15/42

Abstract:

The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.

US Patent:

20140107029, Apr 17, 2014

Filed:

Dec 19, 2013

Appl. No.:

14/133997

Inventors:

- Shorthills NJ, US
H. Bryan Brewer - Potomac MD, US
Hassibullah Akeefe - San Ramon CA, US
Adam Paul Conner - Warsaw IN, US
Timothy Jon Perlman - Pleasanton CA, US

Assignee:

HDL Therapeutics - Shorthills NJ

International Classification:

A61K 38/17

US Classification:

514 74, 422256

Abstract:

The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.